vs
Side-by-side financial comparison of BingEx Ltd (FLX) and IDEAYA Biosciences, Inc. (IDYA). Click either name above to swap in a different company.
IDEAYA Biosciences, Inc. is the larger business by last-quarter revenue ($207.8M vs $143.2M, roughly 1.5× BingEx Ltd). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs 2.2%, a 55.1% gap on every dollar of revenue.
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
FLX vs IDYA — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $143.2M | $207.8M |
| Net Profit | $3.2M | $119.2M |
| Gross Margin | 10.8% | — |
| Operating Margin | — | 52.2% |
| Net Margin | 2.2% | 57.4% |
| Revenue YoY | — | — |
| Net Profit YoY | — | 330.1% |
| EPS (diluted) | — | $1.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $143.2M | — | ||
| Q3 25 | $141.2M | $207.8M | ||
| Q2 25 | $143.0M | — | ||
| Q1 25 | $141.0M | — | ||
| Q3 24 | $164.6M | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $0 | ||
| Q3 22 | — | $29.7M |
| Q1 26 | $3.2M | — | ||
| Q3 25 | $6.1M | $119.2M | ||
| Q2 25 | $7.5M | — | ||
| Q1 25 | $27.6M | — | ||
| Q3 24 | $3.4M | $-51.8M | ||
| Q2 24 | — | $-52.8M | ||
| Q1 24 | — | $-39.6M | ||
| Q3 22 | — | $1.6M |
| Q1 26 | 10.8% | — | ||
| Q3 25 | 11.1% | — | ||
| Q2 25 | 12.0% | — | ||
| Q1 25 | 10.0% | — | ||
| Q3 24 | 11.3% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | — | — |
| Q1 26 | — | — | ||
| Q3 25 | 1.4% | 52.2% | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | — | — | ||
| Q3 24 | 4.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | — | 2.2% |
| Q1 26 | 2.2% | — | ||
| Q3 25 | 4.4% | 57.4% | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | 19.6% | — | ||
| Q3 24 | 2.1% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | — | 5.4% |
| Q1 26 | — | — | ||
| Q3 25 | — | $1.33 | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | $-0.60 | ||
| Q2 24 | — | $-0.68 | ||
| Q1 24 | — | $-0.53 | ||
| Q3 22 | — | $0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $561.1M | $786.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $1.1B |
| Total Assets | $1.3B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $561.1M | — | ||
| Q3 25 | $628.6M | $786.9M | ||
| Q2 25 | $499.4M | — | ||
| Q1 25 | $592.4M | — | ||
| Q3 24 | $517.4M | $920.0M | ||
| Q2 24 | — | $701.7M | ||
| Q1 24 | — | $698.8M | ||
| Q3 22 | — | $386.2M |
| Q1 26 | — | — | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $931.7M | ||
| Q1 24 | — | $935.3M | ||
| Q3 22 | — | $368.8M |
| Q1 26 | $1.3B | — | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q3 24 | $926.8M | $1.2B | ||
| Q2 24 | — | $973.7M | ||
| Q1 24 | — | $961.5M | ||
| Q3 22 | — | $410.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $142.2M |
| Free Cash FlowOCF − Capex | — | $142.2M |
| FCF MarginFCF / Revenue | — | 68.4% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | 1.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | $13.5M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q3 25 | — | $142.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | $-49.2M | ||
| Q2 24 | — | $-32.9M | ||
| Q1 24 | — | $-43.8M | ||
| Q3 22 | — | $-24.2M |
| Q1 26 | — | — | ||
| Q3 25 | — | $142.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | $-49.7M | ||
| Q2 24 | — | $-33.9M | ||
| Q1 24 | — | $-45.1M | ||
| Q3 22 | — | $-25.3M |
| Q1 26 | — | — | ||
| Q3 25 | — | 68.4% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | — | -85.1% |
| Q1 26 | — | — | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | — | 3.7% |
| Q1 26 | — | — | ||
| Q3 25 | — | 1.19× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 22 | — | -14.96× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
